妊娠期Selexipag与肺动脉高压的关系

IHJ Cardiovascular Case Reports (CVCR) Pub Date : 2023-01-01 DOI:10.1016/j.ihjccr.2023.03.001

Sweta Mohanty , Janu Mangala Kanthi , Nitu Puthenveettil , Radhamany Kunjukutty , Shine Kumar

{"title":"妊娠期Selexipag与肺动脉高压的关系","authors":"Sweta Mohanty , Janu Mangala Kanthi , Nitu Puthenveettil , Radhamany Kunjukutty , Shine Kumar","doi":"10.1016/j.ihjccr.2023.03.001","DOIUrl":null,"url":null,"abstract":"<div><p>Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH. Selexipag may be a promising add-on therapy in this unique subset.</p></div>","PeriodicalId":100653,"journal":{"name":"IHJ Cardiovascular Case Reports (CVCR)","volume":"7 1","pages":"Pages 33-35"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Selexipag in pregnancy and pulmonary arterial hypertension\",\"authors\":\"Sweta Mohanty , Janu Mangala Kanthi , Nitu Puthenveettil , Radhamany Kunjukutty , Shine Kumar\",\"doi\":\"10.1016/j.ihjccr.2023.03.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH. Selexipag may be a promising add-on therapy in this unique subset.</p></div>\",\"PeriodicalId\":100653,\"journal\":{\"name\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"volume\":\"7 1\",\"pages\":\"Pages 33-35\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468600X23000105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IHJ Cardiovascular Case Reports (CVCR)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468600X23000105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在患有肺动脉高压（PAH）的女性中，妊娠对母体和胎儿构成了重大风险。由于可供选择的治疗方案极其有限，我们在治疗妊娠合并PAH时，除了使用他达拉非外，还使用了赛拉西帕。Selexipag可能是这一独特亚群中一种很有前途的附加疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Selexipag in pregnancy and pulmonary arterial hypertension

Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH. Selexipag may be a promising add-on therapy in this unique subset.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

IHJ Cardiovascular Case Reports (CVCR)

自引率

0.00%

发文量